Pancreatic cancer remains a fatal disease in the majority of patients. The era of personalized medicine is upon us: customizing therapy according to each patient’s individual cancer. Potentially, therapy can be targeted at individuals who would most likely have a favorable response, making it more efficacious and cost effective. This is particularly relevant for pancreatic cancer, which currently portends a very poor prognosis. However, there is much to be done in this field, and more studies are needed to bring this concept to reality.
- Genomic profile
- Molecular pancreatic pathogenesis
- Pancreatic cancer pharmacogenomics
- Pancreatic exocrine cancer
- Targeted therapy
ASJC Scopus subject areas